iShares 20 Plus Year Treasury Bond ETF vs Zoetis Inc — how do they compare? iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: iShares 20 Plus Year Treasury Bond ETF is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 20 Plus Year Treasury Bond ETF for 83 Days and Zoetis Inc for 70 Days on average.
| TLT | ZTS | |
|---|---|---|
Market Cap | $47.61B | $30.20B |
Volume | 49,263,490 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $92.06 | $147.53 |
52-Week Low | $77.11 | $69.09 |
Typical Hold Time | 83 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.87, up 0.94% on the day but remains in a prolonged downtrend, down 11% year-to-date and 46% over five years. The technical picture is bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights a challenging bond market environment with Treasury yields reaching multi-decade highs, creating headwinds for long-duration bond funds.
The outlook for TLT remains heavily dependent on interest rate direction, with current high yields offering potential income but significant price risk if rates continue rising. Key investment considerations include duration risk exposure, inflation expectations, and Federal Reserve policy shifts. The fund's dividend payments provide income, but capital preservation remains challenging in the current rising rate environment.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →